3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
7
Genitourinary
2
Head & Neck
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Hepatocellular
147
Cholangiocarcinoma
26
Liver Neoplasms
17
Stomach Neoplasms
13
Biliary Tract Neoplasms
13
Parkinson Disease 4, Autosomal Dominant Lewy Body
8
Neoplasms
7
Esophageal Squamous Cell Carcinoma
5
Colorectal Neoplasms
5
Recurrence
4
Pancreatic Neoplasms
4
Neoplasm Metastasis
4
Triple Negative Breast Neoplasms
3
Ovarian Neoplasms
3
Liver Diseases
3
Esophageal Neoplasms
3
Cirrhosis, Familial, with Pulmonary Hypertension
3
Carcinoma
3
Advanced Biliary Tract Cancer
3
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms, Glandular and Epithelial
2
Melanoma
2
Hepatitis B
2
Gallbladder Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Biliary Tract Neoplasms Immunotherapy
2
Uterine Cervical Neoplasms
1
Interventions
pembrolizumab
35
Nivolumab
13
Cyclophosphamide
11
fludarabine
9
aldesleukin
9
atezolizumab
7
Magnetic Resonance Spectroscopy
7
Carboplatin
7
Specimen Handling
6
Ipilimumab
6
Early Intervention, Educational
6
Cisplatin
6
Trastuzumab
5
Paclitaxel
5
Methods
5
Biopsy
5
Bevacizumab
5
durvalumab
4
Vaccines
4
Surveys and Questionnaires
4
Radiotherapy
4
Papillomavirus Vaccines
4
Interleukin-2
4
Docetaxel
4
tisotumab vedotin
3
spartalizumab
3
fludarabine phosphate
3
cemiplimab
3
aflibercept
3
Tomography, X-Ray Computed
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
lenvatinib
×
Gastrointestinal
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled